ERRATUM

The estrogen receptor α -selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice: potential molecular mechanisms

L Lundholm¹, G Bryzgalova², H Gao¹, N Portwood², S Fält¹, K D Berndt¹, A Dicker³, D Galuska⁴, J R Zierath⁴, J-Å Gustafsson¹, S Efendic², K Dahlman-Wright¹ and A Khan²

¹Department of Biosciences and Nutrition, Karolinska Institute, Huddinge, Sweden

²Department of Molecular Medicine and Surgery, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

³Department of Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden

⁴Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

Correspondence should be addressed to L Lundholm: lovisa.lundholm@su.se

Journal of Endocrinology
(2019) **243**, X1

The authors and journal apologise for an error in the above paper, which appeared in volume 199 part 2, pages 275–286. The error relates to Fig. 10, given on page 283. The corrected composite figure for Fig. 10 is given in full below:

Figure 10

Western blot analysis of Stat3, phosphorylated Stat3 on Tyr705 (Stat3P), and glucose-6-phosphatase (G6p) protein in liver of ob/ob mice treated with vehicle or PPT for 30 days ($n = 5$ mice/group). (A) Immunoblots for each respective protein showing the results for individual liver samples from the vehicle-treated or PPT-treated mice. (B) Mean $\pm$ S.E.M. relative abundance for each respective protein in liver of vehicle-treated (open bar) or PPT-treated (filled bar) ob/ob mice ($n = 5$ mice/group). $P = 0.07$, $**P < 0.01$ for PPT-treated versus vehicle-treated ob/ob mice.